Investigational drugs reduce risk of death from Ebola virus disease

The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

- A stockpile of 500,000 doses of Ebola vaccine for emergency use in outbreaks of the deadly fever is being established by the global vaccine alliance GAVI.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Vaccine alliance announces creation of Ebola vaccine stockpile of about 500,000 doses
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
We report a candidate lead (compound #5: ((10R)-10-(4-hydroxyphenyl)-11,12,14,16-tetraazatetracyclo[7.7.0.02,7.011,15] hexadeca-1(16), 2(7),3,5,8,12,14-heptaen-8-ol)) with high drug-likeness score, promising lead-likeness behaviour and high median lethal dose. The candidate lead compound #5 engages in hydrogen bonding and hydrophobic interactions with VP40 active site residues. Thus, the lead compound #5 is recommended for further in vitro and in vivo validations for further consideration. PMID: 31787811 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
Condition:   Ebola Virus Disease Intervention:   Biological: Ad26.ZEBOV vaccine Sponsors:   Universiteit Antwerpen;   Johnson & Johnson;   Ace Africa;   Innovative Medicines Initiative;   Coalition for epidemic prepardness innovations;   University of Kinshasa Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
M. Ververs and M. Gabra
Source: Emerging Infectious Diseases Journal - Category: Infectious Diseases Source Type: research
[The New Humanitarian] Goma, Democratic Republic of Congo -If a doctor referred to you as a "little criminal", would you trust them?
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
(Natural News) In this November 21st story over at the Financial Times they report that largely due to ‘globalization‘ and the ability for people to move from one location to another halfway around the world within hours, deadly contagious diseases such as ‘Ebola‘ have the potential to spread worldwide, very rapidly, with their story also reporting that...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
As the outbreak wanes, one vaccine has been approved and another has entered the next phase of testing
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
(NIH/National Institute of Allergy and Infectious Diseases) The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
This study provides a new view of EBOV uptake and cell polarization, which facilitates a further understanding of EBOV infection and pathogenesis.
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
More News: Clinical Trials | Congo Health | Ebola | Pharmaceuticals